BACKGROUND: This multicenter phase II study was conducted to evaluate the response and safety of a combination of docetaxel plus doxorubicin as neoadjuvant therapy for stage II, III breast cancer. METHODS: Patients with stage II or III breast cancer underwent three cycles of neoadjuvant chemotherapy with doxorubicin 50 mg/m2 and docetaxel 75 mg/m2 every 3 weeks followed by curative surgery. Prophylactic GCSF was not used. RESULTS: Ninety patients were enrolled in the study and 86 were evaluable for efficacy. The median age was 43 years (range, 30-69). The mean relative dose intensity was 0.98 for docetaxel and 0.98 for doxorubicin. Breast-conserving surgery was performed in 12 (13.7%) patients. The clinical overall response rate was 86% and pathologic complete response was 10.5%. Grade 3/4 neutropenia was observed in 26% of total 258 cycles and febrile neutropenia was observed in 15.8%. Pneumonia was observed in one patient and grade 3 mucositis was observed in three patients. CONCLUSION: Docetaxel and doxorubicin was an effective and well-tolerated neoadjuvant chemotherapy for stage II and III breast cancer. Clinical benefit of this treatment will be confirmed by survival data with long term follow up.
BACKGROUND: This multicenter phase II study was conducted to evaluate the response and safety of a combination of docetaxel plus doxorubicin as neoadjuvant therapy for stage II, III breast cancer. METHODS:Patients with stage II or III breast cancer underwent three cycles of neoadjuvant chemotherapy with doxorubicin 50 mg/m2 and docetaxel 75 mg/m2 every 3 weeks followed by curative surgery. Prophylactic GCSF was not used. RESULTS: Ninety patients were enrolled in the study and 86 were evaluable for efficacy. The median age was 43 years (range, 30-69). The mean relative dose intensity was 0.98 for docetaxel and 0.98 for doxorubicin. Breast-conserving surgery was performed in 12 (13.7%) patients. The clinical overall response rate was 86% and pathologic complete response was 10.5%. Grade 3/4 neutropenia was observed in 26% of total 258 cycles and febrile neutropenia was observed in 15.8%. Pneumonia was observed in one patient and grade 3 mucositis was observed in three patients. CONCLUSION:Docetaxel and doxorubicin was an effective and well-tolerated neoadjuvant chemotherapy for stage II and III breast cancer. Clinical benefit of this treatment will be confirmed by survival data with long term follow up.
Authors: Stacy L Moulder; W Fraser Symmans; Daniel J Booser; Timothy L Madden; Cindy Lipsanen; Linda Yuan; Abenaa M Brewster; Massimo Cristofanilli; Kelly K Hunt; Thomas A Buchholz; James Zwiebel; Vicente Valero; Gabriel N Hortobagyi; Francisco J Esteva Journal: Clin Cancer Res Date: 2008-12-01 Impact factor: 12.531
Authors: Taher A Al-Tweigeri; Dahish S Ajarim; Adher A Alsayed; Mohamed M Rahal; Mohamed O Alshabanah; Asma M Tulbah; Osama A Al-Malik; Doha M Fatani; Gamal A El-Husseiny; Naser B Elkum; Adnan A Ezzat Journal: Med Oncol Date: 2009-06-13 Impact factor: 3.064
Authors: Jesus García-Mata; Andres García-Palomo; Lourdes Calvo; Ramon Mel; Juan Jesus Cruz; Manuel Ramos Journal: Clin Transl Oncol Date: 2008-11 Impact factor: 3.405
Authors: Woo Sung Hong; Ja Young Jeon; Seok Yun Kang; Yong Sik Jung; Ji Young Kim; Mi Sun Ahn; Doo Kyoung Kang; Tae Hee Kim; Hyun Ee Yim; Young-Sil An; Rae Woong Park; Ku Sang Kim Journal: J Korean Surg Soc Date: 2013-06-26
Authors: Daniel G Tiezzi; Jurandyr M Andrade; Alfredo Ribeiro-Silva; Fábio E Zola; Heitor R C Marana; Marcelo G Tiezzi Journal: BMC Cancer Date: 2007-02-26 Impact factor: 4.430